RT Journal Article
SR Electronic
T1 Pre-conceptional maternal vitamin B12 supplementation improves offspring neurodevelopment at 2 years of age: PRIYA trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.09.21263316
DO 10.1101/2021.09.09.21263316
A1 D’souza, Naomi
A1 Behere, Rishikesh V
A1 Patni, Bindu
A1 Deshpande, Madhavi
A1 Bhat, Dattatray
A1 Bhalerao, Aboli
A1 Sonawane, Swapnali
A1 Shah, Rohan
A1 Ladkat, Rasika
A1 Yajnik, Pallavi
A1 Kumaran, Kalyanaraman
A1 Fall, Caroline
A1 Yajnik, Chittaranjan S
YR 2021
UL http://medrxiv.org/content/early/2021/09/13/2021.09.09.21263316.abstract
AB Background Nutritional interventions during the first 1000 days of life improves lifelong health. Better pre-conceptional maternal nutrition improves the nutrition of the early embryo. Vitamins B12 and folate are important for fetal neural development. Vitamin B12 deficiency is common in India.Methods In the Pune Rural Intervention in Young Adolescents (PRIYA) adolescents (N=557, 226 females) were provided with vitamin B12 (2µg/day) with or without multiple micronutrients, or a placebo, from preconception until delivery. All groups received mandatory iron and folic acid. We used the Bayley’s Scale of Infant Development (BSID-III) at 24-42 months of age to investigate effects on offspring neurodevelopment. We examined cord blood concentrations of brain-derived neurotropic factor (BDNF).Results Participants in the three groups had similar baseline B12 levels. These improved in the B12 supplemented groups at pre-conceptional and pregnancy (28 weeks gestation) measurements, reflected in higher cord holo-TC levels compared to the placebo. Neurodevelopmental outcomes are available for 74 children. Offspring in the B12 alone group (n=21) performed better than the placebo (n=27) on cognition (p=0.044) and language (p=0.020) domains (adjusted for maternal baseline B12 levels). There were no differences between the B12+MMN (n=26) and placebo group. Cord blood BDNF levels were highest in the B12 alone group (not statistically significant).Conclusion Pre-conceptional vitamin B12 supplementation improved maternal B12 status and offspring neurodevelopment at 2 years of age. The usefulness of cord BDNF as a marker of brain development needs further investigation. Our results highlight the importance of intervening in the pre-conceptional period.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03088189Funding StatementThe PRIYA trial is funded by the Indian Council of Medical Research (58/1/8/ MRC-ICMR/2009/NCD-II) and Medical Research Council, UK (MR/J000094/1) as part of an Indo-UK collaborative call. The biological sample collection and analysis was funded by the DBT-CEIB grant BT/PR12629/MED/97/364/2016 The neurocognitive follow up and cord BDNF measurements was supported by the DBT/Wellcome India Alliance Fellowship [IA/CPHI/161502665] awarded to RB. CSY was visiting professor at Danish Diabetes Academy & Southern University of Denmark (2016-2018) which was funded by NOVO-NORDISK FONDEN. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was approved by the KEM Hospital Research Centre Ethics committee (no 1242) and monitored by a Data Safety Monitoring Board (DSMB) and a Scientific Advisory Committee (SAC). The trial was registered with the CTRI (2012/12/003212) and ISRCTN (32921044). Neurodevelopmental assessment of the offspring was also approved by the Institutional ethics committee of the KEM Hospital research center and registered in (clinical trials.gov ID: NCT03088189).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available from the corresponding author on a suitable request. Data sharing is subject to KEMHRC Ethics Committee approval and Government of India Health Ministry advisory committee permission.